Atovaquone

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Atovaquone
   1. Pharmacist Assessment Report
   2. Atovaquone: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Atovaquone: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Atovaquone, so there is currently no new predicted indication. The uses recorded for this drug are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	3
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
malaria
plasmodium falciparum malaria
pneumocystosis

Australia Market Information

Licence	Product	Dosage form	Status
8300W	Wellvone	Oral suspension 750 mg per 5 mL, 210 mL	Valid

Safety Considerations

• Contraindications suggested by the knowledge graph (not label text): liver failure, liver disease, gallbladder disease, hyperglycaemia, chronic diarrhoeal disease. These should be verified against the Product Information.
• Drug interactions (100 recorded; main moderate-level examples): metoclopramide, naltrexone, tetracycline and picosulfuric acid. Other recorded interactions have unknown severity (for example metformin, omeprazole, morphine, prednisone and vancomycin). A Phase 1 study (NCT01479361) examined how atazanavir-ritonavir and efavirenz affect atovaquone exposure.
• Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---